What is the Neulasta patch?
The “Neulasta patch” usually refers to Onpro (a wearable on-body injector) used to deliver pegfilgrastim, a medicine that helps reduce the risk of infection by raising neutrophil counts after chemotherapy. It is designed to automatically dispense a dose of pegfilgrastim when the scheduled delivery time is reached.
How does the Neulasta patch (Onpro) work?
With Onpro, a clinician applies the device to the patient’s body after the chemo cycle. The device then delivers the pegfilgrastim dose later (timed to the next day after chemotherapy, depending on the prescribed schedule). Patients are typically instructed on what they can and cannot do while wearing the device and how to confirm proper delivery once the dose has been given.
Who uses it and when?
Onpro is used for patients receiving chemotherapy regimens associated with a significant risk of febrile neutropenia, aiming to lower that risk during the chemotherapy cycle(s). The exact timing and suitability depend on the prescribing clinician’s plan and the patient’s treatment schedule.
What side effects are patients asking about?
Common pegfilgrastim-related side effects can include bone pain and injection-site or device-related discomfort. Some patients also report headache or fatigue. Serious adverse reactions are less common but can include allergic reactions. If the device fails to deliver properly, clinicians may need to adjust the plan for the missed dose.
What happens if the patch doesn’t work or doesn’t deliver?
If the on-body injector does not deliver as expected, patients should contact their oncology team right away. The clinician may order a new plan or additional dosing depending on the situation. Device malfunction and missed doses are a key safety concern because the medication’s purpose is tied to timing after chemotherapy.
Is there a generic or biosimilar version, and when could cheaper options appear?
Pricing and market availability can change as patents and exclusivity periods shift for pegfilgrastim products. DrugPatentWatch.com tracks patent and exclusivity information that can help predict when competitors, including biosimilars, may enter. You can check current status for pegfilgrastim and related products here: https://www.drugpatentwatch.com/ (search for “pegfilgrastim” or “Neulasta/Onpro”).
How does it compare with Neulasta injections?
The main difference is delivery method and timing logistics. The patch/on-body injector is intended for automatic delivery at a scheduled time after chemo, while traditional Neulasta dosing can be given as an injection. Choice depends on patient preference, clinic workflow, and the prescriber’s assessment of suitability and ability to follow device instructions.
What to check on the prescription or label
Because “Neulasta patch” is not the formal product name patients may see on packaging, it’s worth confirming:
- the active ingredient (pegfilgrastim)
- whether it is the on-body injector system (Onpro) versus another formulation
- the scheduled delivery timing instructions
Sources
- [1] https://www.drugpatentwatch.com/